| Literature DB >> 22692651 |
J W P Vernooij1, H A H Kaasjager, Y van der Graaf, J Wierdsma, H M H Grandjean, M M C Hovens, G A de Wit, F L J Visseren.
Abstract
OBJECTIVE: To investigate whether an internet based, nurse led vascular risk factor management programme promoting self management on top of usual care is more effective than usual care alone in reducing vascular risk factors in patients with clinically manifest vascular disease.Entities:
Mesh:
Year: 2012 PMID: 22692651 PMCID: PMC3374126 DOI: 10.1136/bmj.e3750
Source DB: PubMed Journal: BMJ ISSN: 0959-8138

Fig 1 Flow chart of study
Baseline characteristics. Values are numbers (percentages) unless stated otherwise
| Intervention group (n=164) | Usual care group (n=166) | |
|---|---|---|
| Mean (SD) age (years) | 60.7 (7.8) | 59.2 (8.9) |
| Male sex | 128 (78) | 118 (71) |
| Mean (SD) body mass index (kg/m²) | 28.2 (4.1) | 27.4 (3.9) |
| Mean (SD) total cholesterol (mmol/L) | 4.7 (1.1) | 4.7 (1.0) |
| Mean (SD) HDL cholesterol (mmol/L) | 1.2 (0.3) | 1.2 (0.3) |
| Mean (SD) triglycerides (mmol/L) | 1.8 (1.1) | 1.7 (1.1) |
| Mean (SD) LDL cholesterol (mmol/L) | 2.8 (0.9) | 2.8 (0.9) |
| Mean (SD) glucose (mmol/L) | 6.3 (1.4) | 6.3 (1.5) |
| Mean (SD) systolic BP (mm Hg) | 140 (18) | 139 (18) |
| Mean (SD) diastolic BP (mm Hg) | 81 (10) | 80 (10) |
| Mean (SD) eGFR (mL/min/1.73 m²) | 80 (18) | 80 (17) |
| Albuminuria | 20 (12) | 20 (12) |
| Coronary artery disease | 75 (46) | 69 (42) |
| Cerebral vascular disease | 44 (27) | 51 (31) |
| Abdominal aortic aneurysm | 7 (4) | 8 (5) |
| Peripheral vascular disease | 38 (23) | 38 (23) |
| Coronary artery disease | 86 (52) | 77 (46) |
| Cerebral vascular disease | 40 (24) | 51 (31) |
| Abdominal aortic aneurysm | 3 (2) | 5 (3) |
| Peripheral vascular disease | 26 (16) | 23 (14) |
| Type 2 diabetes mellitus | 43 (26) | 34 (20) |
| Current smoking | 43 (26) | 44 (27) |
| Family history of cardiovascular disease | 77 (47) | 92 (55) |
| Platelet aggregation inhibitor | 154 (94) | 153 (92) |
| Lipid lowering drug | 142 (87) | 140 (84) |
| Blood pressure lowering drug | 130 (79) | 113 (68) |
| Glucose lowering drug | 29 (18) | 23 (14) |
BP=blood pressure; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein; LDL=low density lipoprotein.
Baseline characteristics of dropouts and analysed patients
| Characteristics | Dropouts (n=16) | Analysed patients (n=314) |
|---|---|---|
| Mean (SD) age (years) | 59.6 (8.0) | 59.9 (8.4) |
| No (%) male | 10 (63) | 236 (75) |
| Mean (SD) body mass index (kg/m²) | 27.5 (4.1) | 27.8 (4.0) |
| Mean (SD) LDL cholesterol (mmol/L) | 3.1 (1.0) | 2.7 (0.9) |
| Mean (SD) systolic blood pressure (mm Hg) | 149 (22) | 139 (18) |
| No (%) current smokers | 4 (25) | 83 (26) |
| Mean (SD) Framingham heart risk score | 18.1 (19.1) | 15.0 (10.6) |
LDL=low density lipoprotein.
Difference in change in Framingham heart risk score and vascular risk factors between intervention group and usual care group
| Risk factor/score | Intervention (n=155) | Usual care (n=159) | Difference* (95%CI) | Relative change† (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | ||||
| Framingham heart risk score | 16.1 (10.6) | 13.2 (8.9) | 14.0 (10.5) | 13.2 (9.4) | −2.1 (−3.8 to −0.3) | −14% (−25% to −2%) | |
| −1.8 (−3.3 to −0.4)‡ | −12% (−22% to −3%)‡ | ||||||
| −1.2 (−2.7 to 0.3)§ | −8% (−18% to 2%)§ | ||||||
| Age (years) | 60.8 (7.9) | — | 59.1 (8.9) | — | |||
| Male sex | 121 (78) | — | 115 (72) | — | |||
| Body mass index (kg/m²) | 28.2 (4.2) | 28.6 (4.1) | 27.5 (3.9) | 27.9 (4.2) | −0.1 (−0.5 to 0.4) | ||
| Total cholesterol (mmol/L) | 4.7 (1.0) | 4.3 (0.9) | 4.7 (1.0) | 4.5 (1.0) | −0.3 (−0.5 to −0.1) | ||
| HDL cholesterol (mmol/L) | 1.2 (0.3) | 1.3 (0.4) | 1.2 (0.3) | 1.3 (0.4) | 0.0 (−0.1 to 0.0) | ||
| Triglycerides (mmol/L) | 1.8 (1.1) | 1.6 (1.2) | 1.7 (1.2) | 1.4 (0.7) | 0.1 (−0.1 to 0.4) | ||
| LDL cholesterol (mmol/L) | 2.8 (0.9) | 2.3 (0.7) | 2.7 (0.9) | 2.6 (0.9) | −0.3 (−0.5 to −0.1) | ||
| Glucose (mmol/L) | 6.3 (1.5) | 6.4 (1.5) | 6.3 (1.4) | 6.3 (1.7) | 0.1 (−0.1 to 0.4) | ||
| HbA1c (%) | 5.8 (0.7) | 5.9 (0.9) | 5.7 (0.7) | 5.9 (0.7) | 0.0 (−0.1 to 0.1) | ||
| Systolic BP (mm Hg) | 140 (17) | 137 (18) | 138 (18) | 140 (19) | −3.7 (−7.6 to 0.2) | ||
| Diastolic BP (mmHg) | 81 (10) | 80 (9) | 79 (10) | 80 (10) | −2.0 (−4.4 to 0.4) | ||
| eGFR (mL/min/1.73 m²) | 80 (18) | 80 (18) | 80 (17) | 79 (17) | 0.9 (−1.6 to 3.4) | ||
| Albuminuria | 20 (13) | 25 (16) | 18 (11) | 18 (11) | 0.7 (−6.6 to 8.1) | ||
Data are expressed as mean (SD) or number (percentage).
BP=blood pressure; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein; LDL=low density lipoprotein.
*Difference between groups=(baseline value–follow-up value in usual care group)−(baseline value–follow-up value in intervention group).
†Relative change calculated by dividing by mean Framingham heart risk score at baseline and multiplying by 100.
‡Adjusted for baseline age, sex, systolic blood pressure, LDL cholesterol, HDL cholesterol, type 2 diabetes mellitus, and current smoking.
§Adjusted for baseline Framingham heart risk score.
Difference in change in risk factors at target and drug use between intervention group and usual care groups
| Intervention (n=155) | Usual care (n=159) | Difference* (95% CI) | ||||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | |||
| Systolic blood pressure <140 mm Hg | 48 | 54 | 50 | 54 | 2.0 (−10.5 to 14.5) | |
| LDL cholesterol <2.5 mmol/L | 39 | 65 | 41 | 48 | 18.4 (5.9 to 30.9) | |
| HDL cholesterol: women ≥1.30, men ≥1.0 mmol/L | 60 | 66 | 69 | 72 | 2.0 (−7.7 to 11.8) | |
| Triglycerides <1.7 mmol/L | 55 | 68 | 64 | 71 | 5.9 (−5.4 to 17.2) | |
| Fasting glucose <6.1 mmol/L | 55 | 52 | 55 | 58 | −6.4 (−16.7 to 3.9) | |
| Body mass index <25.0 kg/m² | 16 | 17 | 26 | 23 | 3.9 (−1.8 to 9.6) | |
| Waist: women <88, men <102 cm | 45 | 42 | 53 | 44 | 2.5 (−7.0 to 12.0) | |
| No smoking | 73 | 78 | 74 | 72 | 7.7 (0.4 to 14.9) | |
| Type 2 diabetes mellitus: | 26 | 28 | 20 | 22 | 0.0 (−5.0 to 5.1) | |
| HbA1c <7%, <53 mmol/mol | 69 | 67 | 78 | 74 | 1.0 (−22.2 to 24.1) | |
| Fasting glucose <8 mmol/L | 60 | 60 | 41 | 57 | −18.9 (−46.4 to 8.6) | |
| Glucose lowering drugs | 65 | 72 | 69 | 74 | −2.5 (−18.9 to 13.8) | |
| Mean (SD) No of risk factors on target† | 2.9 (1.2) | 3.4 (1.2) | 3.1 (1.2) | 3.3 (1.2) | 0.4 (0.1 to 0.6) | |
| Vascular disease treatment‡: | 97 | 99 | 97 | 97 | 2.6 (−2.1 to 7.3) | |
| Platelet aggregation inhibitor | 94 | 98 | 93 | 94 | 2.7 (−3.7 to 9.1) | |
| Lipid lowering drug | 86 | 90 | 86 | 88 | 0.8 (−7.7 to 9.2) | |
| Blood pressure lowering drugs | 79 | 80 | 69 | 75 | −5.0 (−11.7 to 1.6) | |
Data are expressed as percentage or mean (SD).
HDL=high density lipoprotein; LDL=low density lipoprotein.
*Difference=(baseline value–follow-up value in usual care group)−(baseline value–follow-up value in intervention group).
†Risk factors: systolic blood pressure, LDL cholesterol, triglycerides, glucose, body mass index, smoking.
‡Platelet aggregation inhibitors, lipid lowering drugs, blood pressure lowering drugs.
Sensitivity analyses
| Adjustments/subgroups | Difference in FHR between intervention and usual care (95%CI) |
|---|---|
| No adjustments | −2.1 (−3.8 to −0.3) |
| Adjusted for baseline age, sex, SBP, LDL-c, HDL-c, type 2 diabetes, current smoking | −1.8 (−3.3 to −0.4) |
| Adjusted for baseline FHR score | −1.2 (−2.7 to 0.3) |
| FHR score truncated at 1% and 99% | −1.8 (−3.5 to −0.2) |
| Last observation carried forward | −2.1 (−3.8 to −0.4) |
| Men | −2.1 (−4.3 to 0.2) |
| Women | −1.8 (−3.9 to 0.3) |
| Age under 61 years* | −1.7 (−3.5 to 0.1) |
| Age over 61 years | −2.5 (−5.8 to 0.8) |
| No type 2 diabetes mellitus | −1.9 (−3.6 to −0.2) |
| Type 2 diabetes mellitus | −2.1 (−7.2 to 3.1) |
| Body mass index under 27 kg/m²* | −1.5 (−3.7 to 0.8) |
| Body mass index over 27 kg/m² | −2.6 (−5.2 to 0.0) |
| No smoking | −2.7 (−4.3 to −1.0) |
| Smoking | −0.2 (−4.7 to 4.3) |
FHR=Framingham heart risk; HDL-c=high density lipoprotein cholesterol; LDL-c=low density lipoprotein cholesterol; SBP=systolic blood pressure.
*Stratified at median value.
Adverse events
| Events | Intervention group | Usual care group | |||
|---|---|---|---|---|---|
| No of events | No of patients | No of events | No of patients | ||
| All vascular events*: | 18 | 16 | 32 | 24 | |
| Myocardial infarction | 0 | 0 | 6 | 6 | |
| Fatal cerebrovascular event | 0 | 0 | 1 | 1 | |
| Vascular intervention | 18 | 16 | 25 | 20 | |
| Other severe adverse events†: | 26 | 22 | 21 | 16 | |
| Severe bleeding | 1 | 1 | 4 | 4 | |
| Total severe adverse events | 44 | 38 | 53 | 40 | |
| Other adverse events‡ | 17 | 15 | 14 | 4 | |
*Vascular interventions, stroke, myocardial infarction, vascular mortality.
†Death, life threatening events, events requiring at least one night of hospital stay or prolonging of hospital stay, events causing significant invalidity or labour incapacity.
‡Any reported event.

Fig 2 Kaplan-Meier curve for vascular events